A
ACLX
ARCELLX INC
114.89
+0.02+0.02%Opening10:43 04/14 EDT
OPEN/PREV CLOSE114.86/114.87
TODAY RANGE114.86-114.90
VOL149.75K
MARKET CAP6.72B
52 WEEK RANGE47.86-114.94
AVG VOL (3M)2.25M
% TURNOVER0.26%
TURNOVER--
P/E (TTM)-28.2569
% RANGE0.03%
EPS(TTM)-4.0659
P/E(FORWARD)-30.3140
P/B16.54
BVPS6.95
DIVIDEND--
P/S298.65
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP5.69B
SHARES OUTSTANDING58.48M
NEXT EARNINGS05/06-05/11
FREE FLOAT49.49M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Seeking Alpha·4d ago
Gilead projects $107M Q1 earnings headwind due to recent R&D deals
Dow Jones·04/07 14:23
Gilead Buying Another Cancer-Drug Partner -- Market Talk
Dow Jones·04/07 13:55
Gilead Continues Buying Spree with Tubulis Deal -- Market Talk
Seeking Alpha·04/07 13:21
Gilead to acquire Tubulis GmbH for $5B
Dow Jones·04/01 20:35
Gilead Extends Deadline on Tender Offer to Acquire Arcellx
Seeking Alpha·04/01 20:31
Gilead extends Arcellx tender offer expiration date
Reuters·04/01 20:13
Gilead extends Arcellx tender offer deadline to April 24
Reuters·04/01 20:13
GILEAD - TENDER OFFER EXPIRATION EXTENDED TO 5:00 P.M. ET ON APRIL 24, 2026
TipRanks·03/31 15:55
Piper Sandler Remains a Hold on Arcellx Inc (ACLX)
Simply Wall St·03/30 21:05
Assessing Arcellx (ACLX) Valuation After Strong Returns And Fresh Cancer Immunotherapy Data
Simply Wall St·03/27 11:19
Is It Too Late To Consider Arcellx (ACLX) After Its Strong 81% YTD Rally?
Benzinga·03/24 17:58
Gilead Powers Up Its Inflammation Pipeline With Over $1.5 Billion Acquisition
Simply Wall St·03/20 08:07
Assessing Arcellx (ACLX) Valuation After A Sharp Share Price Run And Contrasting DCF Signal
Simply Wall St·03/18 13:09
Is It Too Late To Consider Arcellx (ACLX) After Its Recent Share Price Surge?
Same Industry
Name/Symbol
Change%
Price